日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand

泰国NDV-HXP-S疫苗1/2期随机、安慰剂对照试验的一年随访

Phumratanaprapin, Weerapong; Luvira, Viravarn; Lawpoolsri, Saranath; Cowan, Juthaporn; Muangnoicharoen, Sant; Kamolratanakul, Supitcha; Sabmee, Yupa; Narakorn, Piengthong; Surichan, Somchaiya; Mercer, Laina D; Raghunandan, Rama; Polyak, Christina S; Wirachwong, Ponthip; Flores, Jorge; Innis, Bruce L; Pitisuttithum, Punnee

Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial

在泰国那空帕侬府18-64岁健康成年人中,本地生产的三价灭活流感疫苗(Tri Fluvac)的安全性和免疫原性:一项III期双盲、三组、随机、对照试验

Prasert, Kriengkrai; Praphasiri, Prabda; Lerdsamran, Hatairat; Nakphook, Sutthichai; Ditsungnoen, Darunee; Chawalchitiporn, Sutthinan; Sornwong, Kanlaya; Poopipatpol, Kittisak; Wirachwong, Ponthip; Narakorn, Piengthong; Surichan, Somchaiya; Suthepakul, Nava; Thangsupanimitchai, Napawan; Pittayawonganon, Chakrarat; Puthavathana, Pilaipan; Davis, William W; Mott, Joshua A; Olsen, Sonja J; Patumanond, Jayanton

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

表达 SARS-CoV-2 刺突的灭活重组新城疫病毒疫苗的安全性和免疫原性:一项随机、安慰剂对照的 1 期试验的中期结果

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong, Steven Lamola, Laina D Mercer, Rama Raghunandan, Weina Sun, Yonghong Liu, Juan Manuel C